New drug HRS-1893 tested for Long-Term safety in heart disease patients
NCT ID NCT07021963
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This study is checking the long-term safety of a drug called HRS-1893 in 300 people with hypertrophic cardiomyopathy, a condition where the heart muscle thickens. Participants have already taken HRS-1893 in earlier studies. The main goal is to see how many side effects occur and if the heart's pumping function stays normal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-1893 tablet
What this could lead to
If successful, this could show that HRS-1893 is safe enough to use long-term for managing hypertrophic cardiomyopathy, potentially leading to a new treatment option.
What could go wrong
This is an early-phase study focused on safety, not effectiveness. It may not prove the drug works, and side effects or heart function declines could occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERTROPHIC CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
RECRUITINGBeijing, Beijing Municipality, 100037, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact